vs
科睿唯安（CLVT）与P3 Health Partners Inc.（PIII）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是P3 Health Partners Inc.的1.5倍（$585.5M vs $384.8M），科睿唯安净利率更高（-6.9% vs -19.6%，领先12.8%），P3 Health Partners Inc.同比增速更快（3.8% vs -1.4%），过去两年P3 Health Partners Inc.的营收复合增速更高（-0.5% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
P3 Health Partners Inc.是一家总部位于美国的人口健康管理与价值型医疗服务企业，与基层医疗机构及医疗系统合作，为包括联邦医保优势计划参保者在内的人群提供协同优质医疗服务，致力于提升诊疗效果、降低不必要的医疗开支。
CLVT vs PIII — 直观对比
营收规模更大
CLVT
是对方的1.5倍
$384.8M
营收增速更快
PIII
高出5.2%
-1.4%
净利率更高
CLVT
高出12.8%
-19.6%
两年增速更快
PIII
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $384.8M |
| 净利润 | $-40.2M | $-75.5M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 5.2% | -40.0% |
| 净利率 | -6.9% | -19.6% |
| 营收同比 | -1.4% | 3.8% |
| 净利润同比 | 61.3% | -28.8% |
| 每股收益（稀释后） | $-0.06 | $-23.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTPIII
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $384.8M | ||
| Q3 25 | $623.1M | $345.3M | ||
| Q2 25 | $621.4M | $355.8M | ||
| Q1 25 | $593.7M | $373.2M | ||
| Q4 24 | $663.0M | $370.7M | ||
| Q3 24 | $622.2M | $362.1M | ||
| Q2 24 | $650.3M | $379.2M |
净利润CLVTPIII
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $-75.5M | ||
| Q3 25 | $-28.3M | $-31.6M | ||
| Q2 25 | $-72.0M | $-20.4M | ||
| Q1 25 | $-103.9M | $-20.5M | ||
| Q4 24 | $-191.8M | $-58.6M | ||
| Q3 24 | $-65.6M | $-46.5M | ||
| Q2 24 | $-304.3M | $-12.0M |
毛利率CLVTPIII
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — |
营业利润率CLVTPIII
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | -40.0% | ||
| Q3 25 | 7.1% | -12.8% | ||
| Q2 25 | 1.1% | -9.6% | ||
| Q1 25 | -3.5% | -10.2% | ||
| Q4 24 | -9.4% | -37.4% | ||
| Q3 24 | 3.5% | -29.5% | ||
| Q2 24 | -36.9% | -8.3% |
净利率CLVTPIII
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | -19.6% | ||
| Q3 25 | -4.5% | -9.1% | ||
| Q2 25 | -11.6% | -5.7% | ||
| Q1 25 | -17.5% | -5.5% | ||
| Q4 24 | -28.9% | -15.8% | ||
| Q3 24 | -10.5% | -12.8% | ||
| Q2 24 | -46.8% | -3.2% |
每股收益（稀释后）CLVTPIII
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $-23.08 | ||
| Q3 25 | $-0.04 | $-9.67 | ||
| Q2 25 | $-0.11 | $-6.23 | ||
| Q1 25 | $-0.15 | $-6.28 | ||
| Q4 24 | $-0.27 | $-23.13 | ||
| Q3 24 | $-0.09 | $-15.70 | ||
| Q2 24 | $-0.46 | $-7.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $25.0M |
| 总债务越低越好 | $4.3B | $228.4M |
| 股东权益账面价值 | $4.8B | $-155.2M |
| 总资产 | $10.9B | $656.6M |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTPIII
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $25.0M | ||
| Q3 25 | $318.7M | $37.7M | ||
| Q2 25 | $362.6M | $38.6M | ||
| Q1 25 | $354.0M | $40.1M | ||
| Q4 24 | $295.2M | $38.8M | ||
| Q3 24 | $388.5M | $63.0M | ||
| Q2 24 | $376.4M | $73.1M |
总债务CLVTPIII
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $228.4M | ||
| Q3 25 | $4.4B | $252.8M | ||
| Q2 25 | $4.5B | $182.0M | ||
| Q1 25 | $4.5B | $171.1M | ||
| Q4 24 | $4.5B | $108.9M | ||
| Q3 24 | $4.6B | $133.2M | ||
| Q2 24 | $4.6B | $133.1M |
股东权益CLVTPIII
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $-155.2M | ||
| Q3 25 | $4.9B | $-18.7M | ||
| Q2 25 | $5.0B | $44.5M | ||
| Q1 25 | $5.0B | $63.3M | ||
| Q4 24 | $5.1B | $75.9M | ||
| Q3 24 | $5.5B | $120.5M | ||
| Q2 24 | $5.6B | $166.8M |
总资产CLVTPIII
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $656.6M | ||
| Q3 25 | $11.2B | $683.6M | ||
| Q2 25 | $11.4B | $731.6M | ||
| Q1 25 | $11.5B | $783.9M | ||
| Q4 24 | $11.5B | $783.4M | ||
| Q3 24 | $12.0B | $833.3M | ||
| Q2 24 | $12.1B | $892.8M |
负债/权益比CLVTPIII
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | 4.09× | ||
| Q1 25 | 0.90× | 2.71× | ||
| Q4 24 | 0.88× | 1.43× | ||
| Q3 24 | 0.84× | 1.11× | ||
| Q2 24 | 0.83× | 0.80× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $-25.7M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | — |
| 自由现金流率自由现金流/营收 | 13.5% | — |
| 资本支出强度资本支出/营收 | 9.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $333.9M | — |
8季度趋势，按日历期对齐
经营现金流CLVTPIII
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $-25.7M | ||
| Q3 25 | $181.1M | $-15.4M | ||
| Q2 25 | $116.3M | $-16.6M | ||
| Q1 25 | $171.2M | $-33.5M | ||
| Q4 24 | $141.3M | $-57.2M | ||
| Q3 24 | $202.9M | $-22.6M | ||
| Q2 24 | $126.2M | $-10.2M |
自由现金流CLVTPIII
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $50.3M | — | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $126.3M | — | ||
| Q2 24 | $60.3M | — |
自由现金流率CLVTPIII
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 9.3% | — |
资本支出强度CLVTPIII
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 12.4% | 0.0% | ||
| Q3 24 | 12.3% | 0.0% | ||
| Q2 24 | 10.1% | 0.0% |
现金转化率CLVTPIII
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
PIII
| Capitated Revenue | $366.2M | 95% |
| Health Care Patient Service | $18.6M | 5% |
| Health Care Care Coordination Management Fees | $2.7M | 1% |
